Loading…
Loading…
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG's valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.
First Trust Advisors LP bought a new stake in 10x Genomics (NASDAQ: TXG) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,759 shares of the company's stock, valued at approximately $271,000. Several other large investors have also modified their holdings
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.